biostudies-literatureKarami SSemnan University of Medical Sciences121https://www.ebi.ac.uk/biostudies/studies/S-EPMC8549143biostudies-literatureUnknown13(1)<h4>Background</h4>Non-alcoholic fatty liver disease (NAFLD) patients are at a substantial risk for developing cardiovascular disease (CVD). High-density lipoprotein (HDL) is well known to have protective effects against the development of atherosclerotic CVD. One of the major antiatherogenic effects of HDL is its anti-oxidative function.<h4>Objectives</h4>This study investigated the association of anti-oxidative capacity of HDL with subclinical atherosclerosis in NAFLD and non-NAFLD subjects.<h4>Methods</h4>A total of 143 subjects including 51 NAFLD and 92 control subjects were included in this case-control study. HDL oxidative index (HOI) was determined spectrophotometrically using a cell-free method in the presence of a fluorescent substrate dichlorofluorescein diacetate (DCFDA). ParaoxDiabetology & metabolic syndromeAssociation of anti-oxidative capacity of HDL with subclinical atherosclerosis in subjects with and without non-alcoholic fatty liver disease.PMC85491431556Karami SPakdel ASarmadi NAli Yari FShabani PRadmard ARPoustchi HfalseAssociation of anti-oxidative capacity of HDL with subclinical atherosclerosis in subjects with and without non-alcoholic fatty liver disease.<h4>Background</h4>Non-alcoholic fatty liver disease (NAFLD) patients are at a substantial risk for developing cardiovascular disease (CVD). High-density lipoprotein (HDL) is well known to have protective effects against the development of atherosclerotic CVD. One of the major antiatherogenic effects of HDL is its anti-oxidative function.<h4>Objectives</h4>This study investigated the association of anti-oxidative capacity of HDL with subclinical atherosclerosis in NAFLD and non-NAFLD subjects.<h4>Methods</h4>A total of 143 subjects including 51 NAFLD and 92 control subjects were included in this case-control study. HDL oxidative index (HOI) was determined spectrophotometrically using a cell-free method in the presence of a fluorescent substrate dichlorofluorescein diacetate (DCFDA). Paraox2021-01-01T00:00:00Z2021 Oct2025-04-19T15:33:25.123Z2025-04-19T15:33:25.123ZS-EPMC85491433470232910.1186/s13098-021-00741-5